Country: Canada
Language: English
Source: Health Canada
LACOSAMIDE
SANIS HEALTH INC
N03AX18
LACOSAMIDE
50MG
TABLET
LACOSAMIDE 50MG
ORAL
15G/50G
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0152810001; AHFS:
APPROVED
2021-02-25
_LACOSAMIDE Product Monograph _Page 1 of 42 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LACOSAMIDE Lacosamide Tablets Film-coated tablets, 50 mg, 100 mg, 150 mg and 200 mg, Oral House standard Antiepileptic ATC Code: N03AX18 SANIS HEALTH INC. 1 President's Choice Circle Brampton, Ontario L6Y 5S5 Date of Initial Authorization: February 25, 2021 Date of Revision: August 24, 2023 Submission Control Number: 274418 _LACOSAMIDE Product Monograph _Page 2 of 42 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, 7.1.1 Pregnant Women 08/2023 7 Warnings and Precautions, 7.1.2 Breast-feeding 08/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ....................................................................................................................... 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ......................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ......................................................................................... 4 4.1 Dosing Considerations ............................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ........................................................... 4 4.4 Administration .......................................................... Read the complete document